A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease

Parkinsonism and Related Disorders

Volumn 8, Issue 4, 2002, Pages 271-276

  Jankovic, J ^a   Hunter, C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Neuroprotection; Parkinson's disease; Riluzole

Indexed keywords

PLACEBO; RILUZOLE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION; LONGITUDINAL STUDY; MALE; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REACTION TIME; SAMPLE SIZE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PILOT PROJECTS; PLACEBOS; RILUZOLE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0036164536     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00040-2     Document Type: Article

References (30)

1. New and emerging therapies for Parkinson disease
2. Mitochondrial depolarization in glutamate-stimulated neurons:an early signal to excitotoxin exposure
3. Final common pathways in neurodegenerative diseases: Regulatory role of the glutathione cycle
4. Glutamate and Parkinson's disease
5. Excitatory amino acids as a final common pathway for neurologic disorders
6. Pathophysiology of the basal ganglia in Parkinson's disease
7. Pharmacologic pallidotomy with glutamate antagonists
8. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
9. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease
10. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys
11. Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study
12. Riluzole for levodopainduced dyskinesias in advanced Parkinson's disease
13. Riluzole therapy in Huntington's disease (HD)
14. Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder
15. Benefit of vitamin E, riluzole and gabapentin in transgenic model of familial amyotrophic lateral sclerosis
16. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
17. The unified Parkinson's disease rating scale
18. Movement and reaction times and fine coordination tasks following pallidotomy
19. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
20. The pharmacology and mechanism of action of riluzole
21. Riluzole
22. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study
23. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model
24. Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism
25. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation
26. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
27. Neuroprotective effects of riluzole: An electrophysiological and histological analysis in an in vitro model of ischemia
28. Neuroprotective effects of riluzole in neurotrauma models: A review
29. Lamotrigine trial in idiopathic parkinsonism: A double-blind, placebo-controlled crossover study
30. A randomized, controlled trial of remacemide for motor complication in Parkinson's disease